Given that the analgesic effect of S-ketamine is due to both S-ketamine and norketamine, relatively small oral doses of S-ketamine can be assumed to be a feasible alternative to repeated intravenous dosing, for example in the setting of chronic pain.

Many dog breeds are bred specifically for increased performance in scent-based tasks. Whether dogs bred for this purpose have higher olfactory capacities than other dogs, or even wolves with whom they share a common ancestor, has not yet been studied. Indeed, there is no standard test for assessing canine olfactory ability. This study aimed to create a simple procedure that requires no pre-training and to use it to measure differences in olfactory capacity across four groups of canines: (1) dog breeds that have been selected for their scenting ability; (2) dog breeds that have been bred for other purposes; (3) dog breeds with exaggerated short-nosed features; and (4) hand-reared grey wolves. The procedure involved baiting a container with raw turkey meat and placing it under one of four identical ceramic pots. Subjects were led along the row of pots and were tasked with determining by olfaction alone which of them contained the bait. There were five levels of increasing difficulty determined by the number of holes on the container’s lid. A subsample of both dogs and wolves was retested to assess reliability. The results showed that breeds selected for scent work were better than both short-nosed and non-scent breeds. In the most difficult level, wolves and scenting breeds performed better than chance, while non-scenting and short-nosed breeds did not. In the retested samples wolves improved their success; however, dogs showed no change in their performances indicating that a single test may be reliable enough to assess their capacity. Overall, we revealed measurable differences between dog breeds in their olfactory abilities and suggest that the Natural Detection Task is a good foundation for developing an efficient way of quantifying them.

Global oxycodone consumption has increased sharply during the last two decades, and, in 2008, oxycodone consumption surpassed that of morphine. As oxycodone was synthesized in 1916 and taken to clinical use a year later, it has not undergone the same approval process required by today's standards. Most of the basic oxycodone pharmacokinetic (PK) data are from the 1990s and from academic research; however, a lot of additional data have been published over the last 10 years. In this review, we describe the latest oxycodone data on special populations, including neonates, children, pregnant and lactating women, and the elderly. A lot of important drug interaction data have been published that must also be taken into account when oxycodone is used concomitantly with cytochrome P450 (CYP) 3A inducers and inhibitors and/or CYP2D6 inhibitors. In addition, we gathered data on abuse-deterrent oxycodone formulations, and the PK of alternate administration routes, i.e. transmucosal and epidural, are also described. Mari Kinnunen and Panu Piirainen contributed equally to this work.

Background:There is a controversy regarding the efficacy of rectus sheath block (RSB). The aim of the present study was to evaluate analgesic efficacy and safety of three different methods of RSB in postoperative pain management after midline laparotomy.Methods:A prospective, randomized, controlled, open-label clinical trial with 4 parallel groups was conducted in a tertiary care hospital in Finland. A total of 57 patients undergoing midline laparotomy were randomized to the control group (n = 12) or to 1 of the 3 active RSB analgesia groups: single-dose (n = 16), repeated-doses (n = 12), or continuous infusion (n = 17). Opioid consumption with iv-patient-controlled analgesia pump was recorded, and pain scores and patients’ satisfaction were surveyed on an 11-point numeric rating scale for the first 48 postoperative h. Plasma concentrations of oxycodone and levobupivacaine were analyzed. All adverse events during the hospital stay were recorded.Results:Oxycodone consumption was less during the first 12 h in the repeated-doses and in the continuous infusion groups (P = .07) and in numerical values up to 48 h in the repeated-doses group. Plasma oxycodone concentrations were similar in all 4 groups. Pain scores were lower in the repeated-doses group when coughing during the first 4 h (P = .048 vs. control group), and at rest on the first postoperative morning (P = .034 vs. the other 3 groups) and at 24 h (P = .006 vs. the single-dose group). All plasma concentrations of levobupivacaine were safe. The patients’ satisfaction was better in the repeated-doses group compared with the control group (P = .025). No serious or unexpected adverse events were reported.Conclusions:RSB analgesia with repeated-doses seems to have opioid sparing efficacy, and it may enhance pain relief and patients’ satisfaction after midline laparotomy.